NMF partners with the Bristol Myers Squibb Foundation and the American Association for Cancer Research on the Robert A. Winn Career Development Award (CDA). Launched in 2021, his innovative and bold initiative works to transform the clinical research landscape and enhance the development of therapeutics for all populations by building and strengthening partnerships between clinical investigators and communities and increasing the diversity of patients in clinical trials. In 2022, Gilead Sciences, Inc. committed to donate $14 million over four years as a new program supporter.

This trailblazing two-year career development program will train and develop 250 new community-oriented clinical trialists to become world-class clinical researchers with the additional knowledge, skills, and competencies to engage effectively with communities and foster active community participation in clinical research. The program provides sponsorship, support, training, and mentoring for early-stage investigator physicians to become independent clinical trial investigators who are committed to advancing health equity through their research and mentoring. Enrolled physicians are trained in investigator-initiated and industry-sponsored clinical trials, as well as in community outreach and engagement processes and methods. They are mentored by an experienced principal investigator and will substantively participate in the PI’s active clinical trial. In addition, the program offers a comprehensive and integrated approach to increase diversity in trial sites through a clinical trial site development infrastructure fund.

The Winn CDA also builds the pipeline of diverse clinical researchers by introducing 250 students underrepresented in medicine to clinical research career pathways via a community site-based summer immersion program, the Robert A. Winn Clinical Investigator Pipeline Program Award.

Eligible Candidates

Winn CDA candidates must meet the following eligibility:

  • Hold the degree of MD, MD/PhD, DO or DO/PhD
  • Be a U.S. citizen or lawful permanent resident (LPR) as defined by the U.S. Department of Homeland Security. (NOTE: O-1 & H-1B visa holders are eligible; the visa must be valid throughout the two-year program.)
  • Have interest in clinical research in the areas of cancer, cardiovascular disease, and immunologic disorders
  • Reflect the NIH definition of early-stage investigator
  • Meet the NSF definition of underrepresented populations in the U.S. biomedical, clinical behavioral and social sciences research enterprise, or have a demonstrated commitment to increasing diversity in clinical trials

Application Timeline

  • Letter of intent opened on October 18, 2021, and closed March 15, 2022, at 11:59pm Eastern Time
  • Full application opened (by invitation only) on January 31, 2022, and closes April 29, 2022, at 11:59 pm Eastern Time
  • Award notification: August 1, 2022

* Dates subject to change

For more information please visit: www.diversityinclinicaltrials.org.

260273964 10159844907559374 7129886022741030371 N
Logo that says Bristol Myers Squibb and National Medical Fellowships